Regen-cov™ (casirivimab and imdevimab) phase 3 recovery trial meets primary outcome, improving survival in hospitalized covid-19 patients lacking an immune response to sars-cov-2

Tarrytown, n.y., june 16, 2021 /prnewswire/ -- uk recovery investigators found regen-cov reduced risk of death by 20% in patients hospitalized with covid-19 who had not mounted their own immune response (primary outcome for the primary analysis population) first trial to demonstrate that any antibody treatment improved survival in patients hospitalized with covid-19 regeneron will share new data with regulatory authorities immediately and request that the u.s. eua be expanded to include appropriate hospitalized patients regeneron pharmaceuticals, inc. (nasdaq: regn) today welcomed positive results from the largest trial assessing any monoclonal antibody treatment in patients hospitalized with severe covid-19.
REGN Ratings Summary
REGN Quant Ranking